DSIP 5mg

DSIP, also known as Delta Sleep-Inducing Peptide, is a neuropeptide first discovered in the 1970s. It is naturally produced in the body and plays a role in regulating sleep patterns.

DSIP is believed to induce deep sleep and promote restful and restorative sleep cycles. It has been studied for its potential therapeutic applications, particularly in treating sleep disorders and related conditions such as insomnia.

Research suggests that DSIP may help regulate the release of other hormones in the body, including melatonin and cortisol, which are important for maintaining a healthy sleep-wake cycle. It is thought to promote the production of delta waves in the brain, which are associated with deep sleep.

• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
• Molecular Formula: C35H48N10O15
• Molecular Weight: 848.824 g/mol
• PubChem CID: 68816
• CAS Number: 62568-57-4
• Synonyms: Emideltide, DSIP nonapeptide, Deltaran

Source: PubChem

The Relationship of DSIP to Sleep

DSIP is a neuropeptide studied for its relationship to sleep. Research suggests that DSIP may play a role in promoting deep and restful sleep.

A review published in PubMed highlights that DSIP induces delta-sleep, which is associated with deep sleep, in rabbits, rats, mice, and humans. However, the effects on cats were found to be different.

Plasma DSIP-like immunoreactivity decreased during the transition from wakefulness to sleep, suggesting a potential link between DSIP and sleep stages.

While some studies suggest a correlation between DSIP and the promotion of slow-wave sleep (SWS) and the suppression of paradoxical sleep (PS), other studies show no clear correlation.

The specific mechanisms and exact role of DSIP in sleep regulation are still not fully understood. There is ongoing research to further characterize the relationship between DSIP and sleep.

DSIP Research and Chronic Pain

While there is limited research specifically focused on DSIP and chronic pain, there are some studies that suggest a possible connection.

One study published in the journal "Pain Medicine" explored the effects of DSIP on patients with chronic pain. The researchers found that DSIP administration improved pain intensity and sleep quality in the participants. However, it's important to note that this study had a small sample size, and more research is needed to draw definitive conclusions.

Another study published in the journal "Neuroscience Letters" investigated the analgesic (pain-relieving) effects of DSIP in animal models. The results showed that DSIP administration significantly reduced pain sensitivity in rats, suggesting its potential as a pain management tool. Again, further research is needed to ascertain the efficacy and safety of DSIP in humans.

DSIP Research and Metabolism

DSIP, or Delta Sleep-Inducing Peptide, is primarily known for regulating sleep patterns. While research on DSIP and metabolism is limited, some studies suggest a potential link.

One study investigated the effects of DSIP on lipid metabolism in rats. The researchers found that DSIP administration reduced body weight, fat mass, and serum lipid levels in the rats. This suggests that DSIP may have a modulatory effect on lipid metabolism.

Another study explored the influence of DSIP on glucose metabolism in rats. The findings indicated that DSIP administration improved glucose tolerance and insulin sensitivity in the rats, potentially suggesting a role in regulating glucose metabolism.

However, it's important to note that the research on DSIP and metabolism is still preliminary, and more studies are needed to understand the mechanisms and effects fully. 

Depression, Chemical Imbalances, and DSIP

Depression is a complex mental health condition, and the idea that it is solely caused by a chemical imbalance in the brain is being challenged by recent research. While there is a commonly held belief that imbalances in neurotransmitters like serotonin contribute to depression, studies suggest that the relationship between chemicals in the brain and depression is much more intricate.

According to an analysis by University College London, there is no clear evidence to support the notion that a specific chemical imbalance in the brain causes depression. The study emphasizes the complexity of depression and suggests that multiple factors, including genetic predisposition, life experiences, and environmental influences, play a role in its development.

Similarly, Harvard Health states that while depression is often associated with chemical imbalances, this oversimplification doesn't fully capture the complexity of the disease. Depression is a multifaceted condition influenced by various biological, psychological, and social factors.

However, researchers have uncovered that DSIP regulates monoamine oxidase type A (MAO-A) and serotonin levels, preventing significant alterations. This revelation naturally led scientists to speculate on DSIP's potential impact on depression.

DSIP Research in Withdrawal and Addiction

Research has shown that DSIP administration can lead to the disappearance of clinical symptoms and signs in alcohol and opiate addicts. Furthermore, DSIP has demonstrated promising effects on electrophysiological parameters of sleep during alcohol abstinence.

Studies suggest that DSIP may have a role in reducing withdrawal symptoms and pain states in alcoholics and opiate addicts. It has been used as an adjunct therapy to counteract stress situations and alleviate withdrawal symptoms.

DSIP Research and Cancer Prevention

Cancer prevention strategies typically focus on lifestyle factors such as maintaining a healthy diet, regular exercise, avoiding tobacco and excessive alcohol consumption, and regular screenings. These strategies have been extensively researched and proven effective in reducing the risk of developing certain types of cancer.

Emerging research in mice shows promising potential in cancer prevention for DSIP, or Delta Sleep-Inducing Peptide. In a recent study, female mice received DSIP for five consecutive days each month, starting from 3 months until the end of their lives.

The results were striking: the mice treated with DSIP experienced had a 2.6-fold decrease in tumor development. This substantial reduction in cancer incidence was coupled with a noteworthy 22.6% decline in the occurrence of chromosomal defects in bone marrow.

DSIP Being Tested as Cancer Adjuvant

In recent studies, DSIP (Delta Sleep-Inducing Peptide) has shown potential as a cancer adjuvant, which refers to a substance that enhances the effectiveness of cancer treatment. Chemotherapy can lead to changes in the central nervous system, resulting in various side effects. DSIP is being investigated for its ability to mitigate these changes and potentially improve outcomes.

One study reported that a DSIP-containing preparation called Deltaran exhibited geroprotective and anticarcinogenic effects. Another study found that DSIP impacted respiration, specifically increasing the rate of phosphorylated respiration. These findings suggest that DSIP may have multifaceted properties that could benefit cancer treatment.

DSIP May Have Widespread Physiologic and Muscle-Building Effects

Recent research indicates DSIP may have broader physiological effects, including potential muscle-building benefits.

In a study published, DSIP was found to enhance the release of growth hormone from the pituitary gland, which plays a crucial role in muscle growth and repair. This finding suggests that DSIP may have an indirect impact on muscle-building processes.

Additionally, DSIP has been shown to have analgesic properties, potentially reducing pain and inflammation associated with intense exercise or injury. By alleviating discomfort, DSIP could improve recovery and promote muscle-building processes.

Please note that all the articles and product information provided on this website are intended for informational and educational purposes only.

The products offered on this platform are specifically designed for in-vitro studies, meaning they are conducted outside the body. It is important to clarify that these products are not medicines or drugs, and the FDA has not approved them for the prevention, treatment, or cure of any medical condition, ailment, or disease.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Shlomo Yehuda, Ph.D. has released hundreds of publications relating to the depths of neuroscience, thermoregulation, pharmacology, and the intricacies of colliding mechanisms of action. He specifically studied the effects of mice that consumed DSIP/DSIP-P while being continuously exposed to light, DSIP as a tool for investing the sleep onset mechanism, the peculiar thermoregulatory effects of DSIP at low and high doses, and the effects of DSIP on pain thresholds during light and dark periods in rats.

Shlomo Yehuda, Ph.D. is being referenced as one of the leading scientists involved in the research and development of DSIP. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.